摘要
采用流式细胞计和荧光组织化学法测定了61例新鲜乳腺癌组织细胞DNA倍性及雌激素受体(ER)并分析了DNA倍体类型与ER状况及组织学分级关系。结果表明,61例乳腺癌中,35例为非整倍体癌(57.4％),其余为二倍体癌。ER阳性乳腺癌34例(55.7％)。二倍体乳腺癌多为ER阳性,非整倍体多为ER阴性,二者之间具有显著性关系(P<0.01)。另外,组织分化越差,非整倍体的发生率也越高(P<0.001),乳腺癌细胞集群中ER阳性细胞百分比与DNA非整倍体发生率呈反比关系,随ER阳性细胞比的减少,非整倍体的发生率则显著增加。本组结果提示,DNA倍性可作为估价乳腺癌预后的新指标,将它与ER结合应用,有可能进一步改善乳腺癌的内分泌治疗。
Tumor samples from 61 patients with primary breast cancer were measured for DNA ploidy level and Estrogen Receptor (ER) by flow cytometry and Histochemical fluorescence. Relationship between DNA ploidy Level and ER status was analyzed. The results showed 35 (57.4％) of 61 breast cancer were aneuploidy and remainder were diploidy. 34 (55.7％) of 61 breast cancer were ER-positive, 27 negative. Diploidy tumors were more often ER-positive and high differentiated than aneuploidy tumors (P<0.01and0.001, respectivery). An inverse relationship was also observed, when percentage of ER-positive cell was decreased, the incidence of aneu ptoidy tumors may increased (P<0.001). We suggest that DNA ploidy can be used as a new prognostic marker for breast cancer. If this investigatiOn combied with ER analysis may improved the effect of endocrine therapy in patients with breast cancer.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
1991年第3期145-148,共4页
Cancer Research on Prevention and Treatment
